Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity

NCT00772954 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped Issues with CTM stability.

Conditions

Clostridium Difficile Infection
Clostridium Difficile Diarrhea

Interventions

BIOLOGICAL: Vaccine diluent buffer
BIOLOGICAL: Clostridium difficile toxoid vaccine (50 μg)
BIOLOGICAL: Clostridium difficile toxoid vaccine (100 μg)

Sponsor

Sanofi